Riskpilot← Back to searchSign inGet full accessPhase2Phase Biopharma AB
ABActiveOrg 5593257131Economic activity was not specified by tax authority · NACE 0000Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
98.0%
Financial strength
Net profit 2024
SEK 1,7M
+31% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -47K | +0% |
| Net profit | SEK 1,7M | +31% |
| Total assets | SEK 1,8M | -56% |
| Equity | SEK 1,8M | +17% |
| Employees | 0 | — |
Legal name
Phase2Phase Biopharma AB
Org number
5593257131
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
2 juli 2021
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska äga och förvalta värdepapper i noterade och onoterade bolag och därmed förenlig verksamhet.
Address
Email
contact@phase2phase.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −6 | −46 | −46 | −47 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | −6 | −46 | −46 | −47 |
| Net financials | 1 750 | 1 500 | 1 312 | 1 445 |
| Profit before tax | 1 744 | 1 479 | 1 266 | 1 699 |
| Tax | −0 | — | — | −37 |
| Net profit | 1 744 | 1 479 | 1 266 | 1 661 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 2 543 | 1 879 | 4 159 | 1 812 |
| Equity | 1 769 | 1 748 | 1 514 | 1 775 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 774 | 131 | 2 645 | 37 |
| Total debt | 774 | 131 | 2 645 | 37 |
EBITDA margin
-4650900.0%
This company
15.8%
Market median
-29436176% vs market
20212024
Equity ratio
98.0%
This company
38.2%
Market median
+157% vs market
20212024
Return on equity
93.6%
This company
18.4%
Market median
+409% vs market
20212024
Net profit margin
166149600.0%
This company
8.1%
Market median
+2051229530% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-07-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AM Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Phase2phase Biopharma Holding AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Phase2phase Biopharma Holding AB
Phase2Phase Biopharma AB Board members of Phase2Phase Biopharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Maria Wretholm | Audit | 0 companies |
| Erik Andreas Gretander | Board of Directors | 0 companies |
| Anna Kristina Almkvist | Deputy Board Member | 0 companies |
| Svante Henrik Almkvist | Chairman | 0 companies |
| Åsa Karolina Lindén Gretander | Deputy Board Member | 0 companies |